We are dedicated to the discovery and development of new drugs for treatment of Parkinson’s disease and other life-altering diseases that affect the central nervous system (CNS). We strive to improve the future for patients who, today, lack effective treatment options.
Research and development within CNS
What distinguishes IRLAB’s research and development activities is, in particular, our unique proprietary research platform ISP – Integrative Screening Process. The platform enables discovery and development of therapeutic candidates for diseases related to the central nervous system (CNS). Based on system biology and utilizing machine learning techniques, the methodology differs significantly from conventional detection and development methods in the pharmaceutical industry. To date, all the candidates in IRLAB’s portfolio have been generated through ISP with the most advanced candidates in clinical phase II.
Two clinical programs
The clinical phase II candidates, mesdopetam (IRL790) and IRL752, aims to effectively treat the most troublesome symptoms related to Parkinson’s disease (PD): involuntary movements occurring upon long-term use of levodopa (i.e. LIDs) and impaired balance leading to falls.
Our purpose derives from the great medical need for safe and efficient treatments of diseases related to the central nervous system.
The population of elderly is rapidly growing worldwide and, subsequently, it is expected that diseases triggered by an aging brain such as CNS diseases, e.g. Parkinson’s disease, will increase dramatically. Nearly 13 million people are expected to have developed Parkinson’s disease by 2040, which is more than a two-fold increase since 2015. There is hence an increasingly growing need for new effective treatments, which drives both the development rate of drug candidates as well as the willingness to pay. The total value of all transactions, investments and grants in development projects up to Phase II, the same as IRLAB’s targeted horizon, amounted to USD 4.95 billion in 2018, approximately SEK 44.85 billion.
Headquartered and founded in Sweden
IRLAB has been traded on Nasdaq First North Growth Market since February 2017. The company was founded in 2013 and is based in Gothenburg, Sweden.